Kimberly-Clark Faces Earnings Test as Costs and Consumer Habits Shift

Kimberly-Clark shares have held steady near $130 in recent months. The company faces its next major test in late July when second-quarter earnings arrive. Investors will look for signs that cost pressures and shifts in consumer behavior are easing or building further.

AlphaScala's Alpha Score of 49 out of 100, labeled Mixed, reflects a balanced risk profile. The score suggests no strong catalyst for near-term outperformance or underperformance.

Pulp prices, a major input for the tissue and towel lines, have fallen from 2022 highs but remain above pre-pandemic averages. Oil-based raw materials used in diapers and wipes have stayed elevated. The company's restructuring plan, announced in 2022, aims to deliver $1.5 billion in annual savings by 2025. Progress includes plant closures and supply-chain changes. Wage inflation and higher logistics costs have offset part of those savings.

Consumer spending patterns add another layer. U.S. retail data show a clear tilt toward essentials, which benefits the core categories. At the same time, price sensitivity has increased. Unit sales of branded tissue have slipped in recent months. Private-label share has grown as shoppers trade down.

The personal care segment, which includes Huggies and Kotex, has held up better than the tissue business. Tissue volumes have declined more sharply.

Gross margin contracted sharply in 2022 and has recovered some ground. It remains below historical averages.

Second-quarter results are due in late July. Consensus estimates call for revenue of roughly $5.1 billion and earnings per share of $1.65, according to company filings and analyst surveys. The full-year guidance will be the focal point. The report will show whether the margin recovery is on track and whether private-label pressure is intensifying.

For real-time data and analysis, visit the KMB stock page.